KRT20 antibody (AA 196-323)
Quick Overview for KRT20 antibody (AA 196-323) (ABIN7871725)
Target
See all KRT20 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Grade
Clone
-
-
Binding Specificity
- AA 196-323
-
Purpose
- CK20 Antibody / Cytokeratin 20 / KRT20 (azide and preservative free)
-
Purification
- Protein G affinity chromatography
-
Immunogen
- A portion of amino acids 196-323 from the human protein was used as the immunogen for this CK20 antibody.
-
Isotype
- IgG2b, kappa
-
-
-
-
Application Notes
-
Optimal dilution of the CK20 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store the CK20 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
-
-
- KRT20 (Keratin 20 (KRT20))
-
Alternative Name
- CK20
-
Background
- This mAb recognizes an intermediate filament protein of 46 kDa, identified as Cytokeratin 20 (KRT20, CK20). KRT is abundantly expressed in goblet cells and enterocytes of the gastrointestinal tract. It is a useful marker of pancreatic and colorectal cancer. KRT20 is expressed under normal, hyperplastic and neoplastic conditions. It has been detected in adenocarcinomas of the colon, stomach and biliary tract. Breast carcinomas are generally non-reactive.
-
UniProt
- P35900
Target
-